drugset / Trial / NCT06259903
Subcutaneous Administration of MD-18 in Healthy Subjects
RandomizedSequentialDouble-blindTreatment
Summary
A Single Center, Single Dose, Double-blind, Randomized, Placebo-controlled Dose-Escalating Study to Evaluate Safety, Tolerability and Pharmacokinetics of Subcutaneously Administered MD-18 in healthy subjects.
Timeline
- Start
- 2024-05-07
- Primary completion
- 2024-12
- Completion
- 2025-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MD-18 | Unknown | 40 mg | Subcutaneous |
| Subject | MD-18 | Unknown | 80 mg | Subcutaneous |
| Subject | MD-18 | Unknown | 160 mg | Subcutaneous |
| Subject | MD-18 | Unknown | 240 mg | Subcutaneous |
| Subject | MD-18 | Unknown | 320 mg | Subcutaneous |
Indications
No indication recorded.